Edition:
United States

Aceto Corp (ACET.OQ)

ACET.OQ on NASDAQ Stock Exchange Global Select Market

7.25USD
10:56am EST
Change (% chg)

$-0.08 (-1.09%)
Prev Close
$7.33
Open
$7.31
Day's High
$7.33
Day's Low
$6.99
Volume
76,612
Avg. Vol
130,309
52-wk High
$17.10
52-wk Low
$6.99

Select another date:

Fri, Feb 16 2018

BRIEF-Aceto Appoints Edward Borkowski Chief Financial Officer

* ACETO CORP - APPOINTS EDWARD BORKOWSKI AS CFO EFFECTIVE FEB 21, 2018 Source text for Eikon: Further company coverage:

BRIEF-Aceto Subsidiary, Rising Pharmaceuticals, Launches Atenolol Tablets, 25Mg, 50Mg And 100Mg

* ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES ATENOLOL TABLETS, 25MG, 50MG AND 100MG

BRIEF-Aceto Q2 Loss Per Share $0.39

* IN QUARTER, NET LOSS INCLUDES $13.9 MILLION OF ADDITIONAL INCOME TAX EXPENSE ASSOCIATED WITH TAX CUTS AND JOBS ACT

BRIEF-Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg

* ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES EFAVIRENZ CAPSULES, 50MG AND 200MG

BRIEF-Aceto reports fiscal 2018 first quarter results

* Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S

BRIEF-Aceto corp CFO Douglas Roth notifies co he will retire effective March 31, 2018​

* Says on October 26, Douglas Roth, Chief Financial Officer of Aceto Corporation notified company that he will retire effective March 31, 2018​ Source text : ( http://bit.ly/2yQZ0rq ) Further company coverage:

BRIEF-ACETO SAYS UNIT, RISING PHARMACEUTICALS, LAUNCHES SERTRALINE ORAL SOLUTION, 20MG/ML

* ACETO SUBSIDIARY, RISING PHARMACEUTICALS, LAUNCHES SERTRALINE ORAL SOLUTION, 20MG/ML Source text for Eikon: Further company coverage:

BRIEF-ACETO appoints William Kennally, III president and CEO

* ACETO Corp - ‍Salvatore Guccione, ACETO's chief executive officer has stepped down from all positions with ACETO​ Source text for Eikon: Further company coverage:

BRIEF-Aceto Q4 EPS $0.06

* Aceto reports fiscal 2017 fourth quarter and full year results

Select another date: